Insider / CUMMINS INC
Smith Mark Andrew
VP - Chief Financial Officer at CUMMINS INC
- Company
- CUMMINS INC
- Ticker
- CMI
- First filing on record
- October 8, 2025
- Latest trade on record
- March 1, 2026
- SEC filings
- EDGAR ↗
Smith Mark Andrew, VP - Chief Financial Officer at CUMMINS INC, has disclosed 16 transactions in CMI since October 8, 2025: 0 purchases (0 open-market buys) and 9 sales, worth about $16.2M at the reported prices. The latest was filed March 3, 2026, 2 days after the trade.
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
In the last 12 months Smith Mark Andrew made no purchases and 8 sales worth $9.7M, plus 5 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Smith Mark Andrew has traded 1 stock on record; the largest by dollars is CMI.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
0 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 8 | 21,310 | $9.8M |
| M | Option exercise or conversion | 6 | 42,620 | $3.0M |
| A | Grant or award | 1 | 14,128 | — |
| F | Shares withheld for tax | 1 | 5,878 | $3.4M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 1 · $3.4M |
| 2025 | 14 | 0 | 8 · $9.8M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| CMI | Sell F | March 1, 2026 | March 3, 2026 | 2d | 5,878 | $584 | $3.4M | Form 4 ↗ | ||
| CMI | Other A | March 1, 2026 | March 3, 2026 | 2d | 14,128 | — | — | Form 4 ↗ | ||
| CMI | Option / conversion M | November 6, 2025 | November 10, 2025 | 4d | 13,110 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| CMI | Sell S | November 6, 2025 | November 10, 2025 | 4d | 5,310 | $467 | $2.5M | 10b5-1 plan | Form 4 ↗ | |
| CMI | Sell S | November 6, 2025 | November 10, 2025 | 4d | 3,902 | $473 | $1.8M | 10b5-1 plan | Form 4 ↗ | |
| CMI | Sell S | November 6, 2025 | November 10, 2025 | 4d | 1,320 | $471 | $622K | 10b5-1 plan | Form 4 ↗ | |
| CMI | Sell S | November 6, 2025 | November 10, 2025 | 4d | 975 | $477 | $465K | 10b5-1 plan | Form 4 ↗ | |
| CMI | Sell S | November 6, 2025 | November 10, 2025 | 4d | 803 | $475 | $381K | 10b5-1 plan | Form 4 ↗ | |
| CMI | Sell S | November 6, 2025 | November 10, 2025 | 4d | 800 | $470 | $376K | 10b5-1 plan | Form 4 ↗ | |
| CMI | Option / conversion M | November 6, 2025 | November 10, 2025 | 4d | 13,110 | $142 | $1.9M | 10b5-1 plan | Form 4 ↗ | |
| CMI | Option / conversion M | October 30, 2025 | October 31, 2025 | 1d | 200 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| CMI | Sell S | October 30, 2025 | October 31, 2025 | 1d | 200 | $449 | $90K | 10b5-1 plan | Form 4 ↗ | |
| CMI | Option / conversion M | October 30, 2025 | October 31, 2025 | 1d | 200 | $142 | $28K | 10b5-1 plan | Form 4 ↗ | |
| CMI | Option / conversion M | October 6, 2025 | October 8, 2025 | 2d | 8,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| CMI | Sell S | October 6, 2025 | October 8, 2025 | 2d | 8,000 | $439 | $3.5M | 10b5-1 plan | Form 4 ↗ | |
| CMI | Option / conversion M | October 6, 2025 | October 8, 2025 | 2d | 8,000 | $142 | $1.1M | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| March 3, 2026 | Form 4 | 0001225208-26-003041 | 2 | published | EDGAR ↗ |
| November 10, 2025 | Form 4 | 0001225208-25-009056 | 8 | published | EDGAR ↗ |
| October 31, 2025 | Form 4 | 0001225208-25-008826 | 3 | published | EDGAR ↗ |
| October 8, 2025 | Form 4 | 0001225208-25-008542 | 3 | published | EDGAR ↗ |
Other insiders at CUMMINS INC
- Bush Jennifer Mary VP & Pres. - Power Systems 16 rows
- Lamb-Hale Nicole VP, CLO & Corporate Secretary 16 rows
- Davis Amy Rochelle VP & Pres. - Accelera and Com 14 rows
- JACKSON DONALD G VP - Treasury & Tax 12 rows
- MILLER WILLIAM I Director 10 rows
- Stone John H President and CEO 9 rows
- Boakye Marvin VP - Chief Human Resources Off 8 rows
- Fetch Bonnie J EVP & President - Operations 8 rows
- Harris Carla A Director 8 rows
- RUMSEY JENNIFER Chair and CEO 8 rows
Everyone on file, with contracts and lobbying under the company's name: CUMMINS INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 16 | October 8, 2025 | March 3, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.